TheWealthWeb

Nippon India Pharma Fund Regular Bonus

Nippon India Mutual FundEquity Schemes - Sectoral FundRegular · BonusRisk: Very High

NAV ₹585.2465 on 13 November 2026

AMFI name: Nippon India Pharma Fund-Growth Plan-Bonus Option · Scheme code 102432

1 year
+13.11%
3 years, a year
+17.50%
5 years, a year
+14.23%
Since 18 Oct 2021, a year
+13.34%

IDCW option: returns are NAV changes and leave out payouts, so they understate what investors received. Risk ratios are not shown for payout options.

NAV performance, last year

Returns

To 13 November 2026. Up to 1 year: total change. 3 and 5 years: compound return a year.

PeriodThis fundNIFTY HEALTHCARE INDEX TRICategory median
1M+8.65%+8.67%+8.25%
6M+7.40%+12.84%+9.28%
1Y+13.11%+38.92%+4.48%
3Y+17.50%+28.05%+15.37%
5Y+14.23%-+13.85%

Benchmark: NIFTY HEALTHCARE INDEX TRI (total return index), measured over the same dates. The scheme document names BSE Healthcare TRI, which we do not hold, so this is the closest NSE index.

Category median: the middle return among Regular plans (Growth option) in AMFI's “Equity Schemes - Sectoral Fund” category, up to 20 funds with clean data. Ranks are under “Rank among peers”.

Rank among peers

Regular plans, Growth option, in AMFI's “Equity Schemes - Sectoral Fund” category. Each rank counts only the peers that have that figure.

Compare with Top Peers
3-Year Return Rank
-of 8
+17.50%
N/A
Q1
Q2
Q3
Q4
1-Year Return Rank
-of 8
+13.11%
N/A
Q1
Q2
Q3
Q4
Sharpe (Risk-Adjusted)
-of 8
-
N/A
Q1
Q2
Q3
Q4
Highest 3-year returns in the categoryRegular plans · Growth option
RankScheme Name3Y Return1Y ReturnSharpeDirect TERAUM
#1
Nippon India Mutual Fund
+46.52%+60.64%1.071.06%₹1,100 Cr
#2
HDFC Mutual Fund
+33.64%+20.34%1.070.89%₹11,128 Cr
#3
HDFC Mutual Fund
+31.28%+31.60%1.761.03%₹3,128 Cr
#4
SBI Mutual Fund
+25.42%+26.07%1.470.76%₹5,565 Cr
#5
HDFC Mutual Fund
+24.77%+10.10%1.091.10%₹1,997 Cr
#6
Mirae Asset Mutual Fund
+24.42%+27.89%1.28-₹3,458 Cr
#7
UTI Mutual Fund
+23.89%+22.00%1.311.35%₹1,399 Cr
#8
ICICI Prudential Mutual Fund
+22.73%+10.29%0.952.08%₹3,926 Cr
#-
Nippon India Pharma FundCurrent Fund
Nippon India Mutual Fund
+17.50%+13.11%-1.00%₹9,272 Cr

Costs and fund facts

Expense ratio (stated maximum)
Direct 1.00% · Regular 1.84%
Exit load
1% if redeemed or switched out on or before completion of 1 month from the date of allotment of units.Nil, thereafter.
Fund size (all plans)
₹9,272 CrAverage, quarter to September 2026
Benchmark
BSE Healthcare TRICompared here with NIFTY HEALTHCARE INDEX TRI
Allotment date
5 June 2004Scheme document
Type
Open
AMFI scheme code
102432

Fund manager

  • Sailesh Raj Bhan

How each manager has done since taking over: fund manager scorecard.

Investment objective

The primary investment objective of the scheme is to seek to generate consistent returns by investing in equity and equity related or fixed income securities of Pharma and other associated companies. There is no assurance that the investment objective of the Scheme will be achieved.

From the scheme summary document filed with AMFI.

SIP calculator

A monthly SIP replayed on this fund's actual daily NAVs: what it would be worth today.

IDCW option: values use the NAV only and leave out the payouts, so they understate what an investor received. The Growth option of this fund shows the full return.

Monthly SIP Amount₹10,000
Investment Horizon5 Years
Simulating monthly 1st from 15 Nov 2021 to 13 Nov 2026
Total Invested61 mos
₹6,10,000
Units: 1,589.138
Current Portfolio Value
₹9,30,038
At latest recorded NAV
Total Profit
+₹3,20,038
+52.5% absolute return
SIP XIRR
16.91%
Annualised, money-weighted
Wealth CompositionProfit is 52% of total invested capital
Invested: ₹6,10,000Profit Generated: ₹3,20,038
Same SIP in the benchmark (NIFTY HEALTHCARE INDEX TRI)Same dates & amounts
Scheme SIP Valuation
₹9,30,038
16.9% XIRR
Benchmark SIP Valuation
₹5,56,767
25.8% XIRR
Fund minus benchmark
+₹3,73,271
Over 61 monthly installments
SIP instalments are bought on the first NAV date of each month; values use the latest NAV we hold. Past returns are not a guide to future returns.

About this fund

Nippon India Pharma Fund Regular Bonus is a mutual fund scheme from Nippon India Mutual Fund, listed by AMFI under “Equity Schemes - Sectoral Fund”. This page covers the Regular plan with the Bonus option. Its NAV was ₹585.2465 on 13 November 2026. Its NAV changed by 13.11% over 1 year, 17.50% a year over 3 years and 14.23% a year over 5 years. These figures leave out IDCW payouts, so they understate what investors received. Its benchmark, NIFTY HEALTHCARE INDEX TRI, returned 28.05% a year over 3 years. The fund house rates its risk as “Very High” on the SEBI riskometer. Its average assets under management were ₹9,272 Cr across all plans for the quarter ending September 2026, as reported to AMFI. Its scheme summary document states a maximum expense ratio (TER) of 1.84% a year for the Regular plan. Managed by Sailesh Raj Bhan. Its scheme summary document gives the allotment date as 5 June 2004.

Figures are calculated from AMFI NAVs and index data, not taken from fund factsheets. Methodology. Past performance is not a guide to future returns.

Plans and options of this fund (5)

PlanOptionISINAMFI codeNAV
DirectGrowthINF204K01I50118759₹659.4813 Nov 2026
DirectIDCWINF204K01I43118756₹180.4813 Nov 2026
RegularGrowthINF204K01968102431₹585.2513 Nov 2026
RegularIDCW-102433₹126.3813 Nov 2026
DCW Plan ReinvestmentIDCWINF204K01943--